Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Gene therapy for patients with adenosine deaminase (ADA) deficiency has become practical in the 1990s, and the exogenous gene has been reported to survive for several years in the recipient genome. To evaluate the integration efficiency of the ADA gene (ADA) into peripheral blood lymphocytes (PBL) of a patient with ADA deficiency who is receiving gene therapy, we performed two-color interphase fluorescence in situ hybridization (FISH) analysis by using digoxigenin-labeled ADA-cDNA and the biotin-labeled lambda-genomic ADA clone as probes. After each of 9 sequential series of gene therapy, interphase nuclei of 100 mononuclear cells from the patient were analyzed, and those of a LASN-producing cell line were used as a control. FISH signals were detected with rhodamine and FITC for the cDNA and the genomic DNA, respectively. The number of PBL giving a transgene signal grew after the sequential gene therapies, and the proportion of signal-positive cells reached about 10%. Our results indicate that the two-color FISH system can be used as a potential aid to monitor the efficiency of the ADA gene therapy.
Egashira
M
M
Department of Human Genetics, Nagasaki University School of Medicine, Japan. f0932@nagasaki-u.ac.jp
Ariga
T
T
Kawamura
N
N
Miyoshi
O
O
Niikawa
N
N
Sakiyama
Y
Y
D016475:3T3 Cells; D000243:Adenosine Deaminase / Q000097:blood / Q000235:genetics*; D000818:Animals; D002675:Child, Preschool; D015316:Genetic Therapy / Q000379:methods*; D015894:Genome, Human; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase / Q000235:genetics; D008297:Male; D051379:Mice; D016511:Severe Combined Immunodeficiency / Q000235:genetics* / Q000628:therapy*; D019076:Transgenes / Q000235:genetics
D000243:Adenosine Deaminase